Abstract

287MO Real-world experience with maintenance PARP inhibitor plus minus bevacizumab in newly diagnosed advanced ovarian cancer with germline BRCA mutations or homologous recombination deficiency (HRD) positive

Full Text
Published version (Free)

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call

Similar Papers

Paper Title
Journal
Date
Author
#889 Effect of BRCA or HRD status on the efficacy of hyperthermic intraperitoneal chemotherapy in advanced epithelial ovarian cancer
Upasana Palo ... Jaydip Bhaumik
International journal of gynecological cancer : official journal of the International Gynecological Cancer Society | VOL. 33
Upasana Palo, et. al.Upasana Palo ... Jaydip Bhaumik
01 Sep 2023
PARP inhibitor and chemotherapy combination trials for the treatment of advanced malignancies: does a development pathway forward exist?
U.A Matulonis ... B.J Monk
Annals of oncology : official journal of the European Society for Medical Oncology | VOL. 28
U.A Matulonis, et. al.U.A Matulonis ... B.J Monk
01 Mar 2017
Abstract P3-07-29: Role of germline BRCA status and tumor homologous recombination (HR) deficiency in response to neoadjuvant weekly paclitaxel followed by anthracycline-based chemotherapy
...
American Journal of Cancer | VOL. 76
, et. al. ...
15 Feb 2016
Abstract A074: Correlation of homologous recombination deficiency (HRD) status by BROCA-HR sequencing with response to combination cediranib and olaparib in relapsed ovarian cancer
Joyce F Liu ... Elizabeth M Swisher
Molecular Cancer Therapeutics | VOL. 18
Joyce F Liu, et. al.Joyce F Liu ... Elizabeth M Swisher
01 Dec 2019
View more papers

More From: Annals of oncology : official journal of the European Society for Medical Oncology

Paper Title
Journal
Date
Author
Challenging immune exhaustion in early recurrent triple-negative breast cancer: pitfalls and hopes
P Tarantino ... S M Tolaney
Annals of oncology : official journal of the European Society for Medical Oncology | VOL. 35
P Tarantino, et. al.P Tarantino ... S M Tolaney
01 Jul 2024
Proofreading the way: immune checkpoint inhibitors in polymerase ε/polymerase δ (POLE/POLD1)-altered colorectal cancer
M Cecchini ... R Sundar
Annals of oncology : official journal of the European Society for Medical Oncology | VOL. 35
M Cecchini, et. al.M Cecchini ... R Sundar
01 Jul 2024
Table of Contents
-
Annals of oncology : official journal of the European Society for Medical Oncology | VOL. 35
--
01 Jul 2024
Editorial Board
-
Annals of oncology : official journal of the European Society for Medical Oncology | VOL. 35
--
01 Jul 2024
View more papers